Tiglien-3-one derivatives
AssigneeQbiotics Pty Ltd
InventorsPaul Warren Reddell, Victoria Anne Gordon
Life of this patent
Estimating the term…
Abstract
The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment
Claims21
1-20. (canceled)
A method of treating a cell proliferative disorder, comprising:
- administering to a subject in need thereof an effective amount of 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:
- .
The method of 21, wherein the cell proliferative disorder is a dermatological neoplasm.
The method of 21, wherein the subject is a human.
A method of treating a cell proliferative disorder comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:
- and a pharmaceutically acceptable carrier, diluent and/or excipient.
12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:
- .
A pharmaceutical composition comprising 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one having the structure:
- and a pharmaceutically acceptable carrier, diluent and/or excipient.
Dependencies are inferred from the claim text.